Rapport Therapeutics RAPP 深 沪
等待开盘 04-02 09:30:00 美东时间
31.67
+0.380
+1.21%
华盛通- 最 高32.49
- 今 开31.40
- 成交量 28.78万股
- 最 低 30.95
- 昨 收 31.29
- 总市值 15.14亿
- 52周最高 42.2685
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 7.73
- 委 比 -56.08%
- 总股本 4779.29万
- 历史最高 42.2685
- 量 比 0.83
- 振 幅 4.92%
- 历史最低 6.43
- 每 手 1
- 风险率 7.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics will present Phase 2a results for RAP-219, a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator, at the 2026 AAN Annual Meeting. The presentation will highlight efficacy and tolerability data in patients with focal onset seizures, with potential applications in epilepsy, bipolar disorder, and chronic pain. RAP-219 targets brain regions linked to seizures while minimizing hindbrain activity, o...
04-01 11:00
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Rapport Therapeutics Q4 EPS $(0.72) Misses $(0.69) Estimate
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.69) by 5.11 percent. This is a 26.32 percent decrease over losses of $(0.57) per share
03-10 19:23
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 20 (Reuters) - U.S. stock index futures tumbled more than
03-09 21:29
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
Rapport Therapeutics and Tenacia Biotechnology have entered a collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China. RAP-219, a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator, is being developed for focal onset seizures and bipolar mania. Rapport will receive a $20 million upfront payment, up to $308 million in milestones, and tiered royalties. Tenacia's experti...
03-09 11:00
美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
Wells Fargo Initiates Coverage On Rapport Therapeutics with Overweight Rating, Announces Price Target of $43
Wells Fargo analyst Benjamin Burnett initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Overweight rating and announces Price Target of $43.
02-02 22:47
Rapport Therapeutics Plans to Initiate Its Phase 3 Program for RAP-219 in Focal Onset Seizures in Q2 of 2026 and Expand Its Epilepsy Portfolio With New Program in Primary Generalized Tonic-Clonic Seizures
CLINICAL AND PIPELINE UPDATESRapport is prioritizing programs it believes have the greatest potential to deliver meaningful impact for patients and long-term value for the Company. This disciplined approach positions the
01-07 20:12
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Rapport Therapeutics Announces New Data And Post Hoc Analysis On Clinical And Patient Reported Benefits Of RAP-219 In Drug-Resistant FOS, Alongside Topline Efficacy And Safety Data From Phase 2a FOS Trial
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients' disease
2025-12-05 22:03
